Immunotherapy in Acute LymphoBLASTic Leukemia: TOWERing INOVATEions

Rochester, NY US
March 18, 2020

This activity will provide an overarching review of ALL pathophysiology, diagnosis, and current treatment modalities in both the initial and relapsed/refractory setting. We will then discuss new literature surrounding the use of both inotuzumab ozogamicin and blinatumomab in ALL, and where these treatments fall into our current practice. This activity will provider pharmacists the opportunity revisit the management of patients with ALL, in particular, for those who practice outside of the scope of oncology. Additionally, attendees will be granted the opportunity to apply the knowledge gained in regards to our new immunotherapy options through active learning activities and open discussion.

Target Audience

  • Pharmacists

Learning Objectives

  1. Review the pathophysiology, clinical manifestations, and current treatment modalities for acute lymphoblastic leukemia (ALL)
  2. Define minimal residual disease (MRD), and describe its utility in guiding treatment decisions for patient with ALL
  3. Discuss the role of emerging immunotherapy options in the treatment of ALL
  4. Evaluate current literature surrounding the use of inotuzumab ozogamicin and blinatumomab in patients with ALL

Additional Information

Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 General CEU – Attendance
Course opens: 
Course expires: 
Event starts: 
03/18/2020 - 7:00am CDT
Event ends: 
03/18/2020 - 8:00am CDT
University of Rochester Medical Center
601 Elmwood Avenue
Rochester, NY 14642
United States
Relevant financial relationships: Planning committee members and presenters have nothing to disclose
Planning committee members
Linda Thomas, PharmD, BCPS
Pharmacy Residency Coordinator
University of Rochester Medical Center
Carissa Treptow, PharmD, BCOP
Clinical Pharmacy Specialist, Malignant Hematology
University of Rochester Medical Center
Course reviewer
Katrina K. Harper, PharmD, MBA, BCPS, BCSCP
Clinical Pharmacy Director, Sourcing Operations
Center for Pharmacy Practice Excellence
Sarah Bisesi, PharmD
PGY1 Pharmacy Resident
University of Rochester Medical Center
Joint Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and University of Rochester Medical Center.  Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statements:
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-0000-20-048-L01-P
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 General CEU – Attendance


Please login or register to take this course.